Cerebellum Linked to Schizophrenia's Most Disabling Symptoms

(MENAFN) Scientists at the University of Geneva have uncovered a groundbreaking connection between the cerebellum and schizophrenia's most debilitating manifestations, potentially unlocking pathways to innovative non-invasive therapeutic approaches.

A research team from the institution and Geneva University Hospitals documented for the first time how the cerebellum interacts with the brain's reward mechanisms in individuals living with schizophrenia, according to findings released Tuesday.

While schizophrenia impacts approximately 1% of the global population and commonly presents through hallucinations and delusions, researchers emphasized that the disorder's "negative" symptoms—encompassing apathy, motivational deficits, and social isolation—prove far more incapacitating yet remain poorly addressed by existing treatments.

"We show that stronger cerebellar regulation of the reward system is associated with a reduction in negative symptoms — and conversely, weaker regulation with an increase in symptoms," Jade Awada, first author of the study, said. "This newly identified mechanism opens up promising avenues for targeted therapeutic interventions."

Scientists concentrated their investigation on the ventral tegmental area (VTA), a dopamine-generating brain region governing motivation and reward responses, which operates at heightened levels in schizophrenia patients.

Through monitoring 146 patients across three-to-nine-month intervals and examining a separate cohort, the research team pinpointed a functional pathway linking the cerebellum to the VTA, the statement indicated.

"What is sometimes called our 'little brain' actually contains 50% of all our neurons," said Indrit Begue, who led the study. "Although it was long considered to have a purely motor function, we are now discovering that it also plays important emotional and cognitive roles."

Unlike the VTA, the cerebellum offers significantly greater accessibility, positioning it as a viable candidate for non-invasive interventions including transcranial magnetic stimulation.

A randomized controlled clinical trial is currently underway, with outcomes anticipated by 2028, researchers confirmed.

MENAFN14012026000045017169ID1110596641